Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 9
Summary
- Conditions
- Advanced Cancer
- Advanced Solid Tumor
- Metastatic Cancer
- Recurrent Cancer
- Refractory Cancer
- Solid Tumor, Adult
- Unresectable Carcinoma
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 75 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03941262
- Collaborators
- Not Provided
- Investigators
- Study Director: Steven S. Cha, MD NKGen Biotech, Inc.
Get Well Soon